Selected Presentations & Appearances
Inflammasome-Wnt Ligand Signaling Axis Promotes Immune Escape During Anti-PD-1 Antibody Immunotherapy.
- 2018 Annual Conference
· November 7, 2018
Invited Talk
Society for Immunotherapy of Cancer,
Washington, DC
Tumor-mediated Modulation of Immunometabolism as a Mechanism of Immunotherapy Resistance.
- Immuno-Oncology Summit
· August 27, 2018
- August 27, 2018
Invited Talk
CHI,
Boston, MA
Investigating the Role of Innate Immunity in Adaptive Resistance to Cancer Immunotherapy
- Biomarkers and Immuno-Oncology World Congress
· June 13, 2018
- June 13, 2018
Invited Talk
CHI,
Boston, MA
Role of the Wnt-β-catenin Signaling Pathway in Tumor-mediated Immune Evasion and Immunotherapy Resistance
· March 27, 2018
- March 29, 2018
Invited Talk
Duke-NUS,
Singapore
Uncovering the Role of the Wnt-β-catenin Signaling Pathway in Driving Melanoma Immune Evasion and Immunotherapy Resistance
- 2018 Duke Solid Tumor Therapeutics Program Annual Retreat.
· March 19, 2018
- March 19, 2018
Invited Talk
Duke University,
Durham, NC
Uncovering the Role of the Wnt-β-catenin Signaling Pathway in Driving Melanoma Immune Evasion and Immunotherapy Resistance
- 2018 Pinnel Center Talk
· March 2, 2018
- March 2, 2018
Invited Talk
Duke University,
Durham, NC
The Immune System and Cancer: Mechanisms of Immune Suppression
- ASCO-SITC Lecture
· June 1, 2017
- June 2, 2017
Invited Talk
ASCO ,
McCormick Place, Chicago, IL
Utilizing Pre-Clinical Melanoma Models to Design Rational Combinatorial Immunotherapy Regimens : Lessons Learned from Targeting the TGF-������ Signaling Pathway.
- 2017 Melanoma Research Alliance Annual Meeting
· February 14, 2017
- February 15, 2017
Invited Talk
Melanoma Research Alliance,
Washington, DC
Utilizing Pre-Clinical Melanoma Models to Design Rational Combinatorial Immunotherapy Regimens : Lessons Learned from Targeting the TGF-������ Signaling Pathway.
- 2017 Melanoma Research Alliance Annual Meeting
· February 14, 2017
- February 15, 2017
Invited Talk
Melanoma Research Alliance,
Washington, DC
Utilizing Pre-Clinical Melanoma Models to Design Rational Combinatorial Immunotherapy Regimens : Lessons Learned from Targeting the TGF-������ Signaling Pathway.
- 2017 Melanoma Research Alliance Annual Meeting
· February 14, 2017
- February 15, 2017
Invited Talk
Melanoma Research Alliance,
Washington, DC
The Wnt5a-β-catenin Pathway Triggers a Metabolic Switch That Drives Indoleamine 2,3-dioxygenase Activity and Dendritic Cell Tolerization in the Melanoma Microenvironment.
- Society for Immunotherapy of Cancer 2016 Annual Meeting
· November 11, 2016
- November 13, 2016
Invited Talk
Society for Immunotherapy of Cancer (SITC),
Washington, DC
Targeting the TGF-β Signaling Pathway to Augment the Efficacy of Immunotherapy Checkpoint Inhibitors in Melanoma.
- 2nd Annual Summit on Melanoma
· September 18, 2015
- September 20, 2015
Invited Talk
DAVA Oncology,
The Langham Hotel, Pasadena, CA
Basic Mechanisms of Tumor Immune Suppression
- SITC Regional Advances in Cancer Immunotherapy
· May 29, 2015
- May 29, 2015
Lecture
Society for Immunotherapy of Cancer,
McCormick Place, Chicago, IL
Modulating the Immune Response.
- SITC Regional Advances in Cancer Immunotherapy
· October 3, 2014
- October 4, 2015
Lecture
Society for Immunotherapy of Cancer,
Charlotte, NC
Exploring Dendritic Cell-Targeted Immune Evasion Mechanisms in Melanoma: Developing Pharmacological Strategies to Synergistically Enhance Immunotherapy Efficacy
· August 22, 2014
- August 23, 2014
Invited Talk
Georgia Regents University,
Georgia Regents University, Augusta, GA
Service to the Profession
Manuscript Reviewer
- Journal of Clinical Investigation
·
January 1, 2014
- November 1, 2015
Editorial Activities
Manuscript Reviewer
- Frontiers in Immunology
·
2014
Editorial Activities
Manuscript Reviewer
- Cancer Immunology Immunotherapy
·
2014
Editorial Activities
Manuscript Reviewer
- Plos One
·
January 1, 2013
- November 24, 2015
Editorial Activities
Service to Duke
Pharmacology and Cancer Biology Chair Search Committee
(Department)
·
2021
- 2022
Committee Service
·
2017
Committee Service
Duke University ,
Clinical Activities
Manage patients with advanced skin cancers including melanoma, Merkel cell carcinoma, squamous cell carcinoma, and basal cell carcinoma. One full clinic day weekly. In-patient advanced skin cancer consults.